新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 投资 » Parexel收购Atlas扩展在中东地区业务

Parexel收购Atlas扩展在中东地区业务

来源:生物谷 2014-07-04 15:22

2014年7月4日讯 /生物谷BIOON/ --合约研究机构Parexel公司最近宣布公司收购了土耳其合约研究机构Atlas Medical Services公司以拓展其在中东和北非的业务市场。Parexel公司并未透露合约设计的具体细节,仅表示收购后的业务将会并入现有的研究机构。根据合约Parexel公司将获得Atlas公司在伊斯坦布尔等三个城市的研究机构和35名研究人员。去年Atlas收入约为400万美元。尽管Atlas公司的规模很小,但是其客户遍布世界各地,其中还包括一些重量级的医药产业巨头。

Parexel公司今年预计会迎来一个出色的财报,公司2015财政年度的收入预计将达到22亿美元,比前一年增长了10%。(生物谷Bioon.com)

详细英文报道:

Parexel International ($PRXL) is looking to broaden its presence in the Middle East and North Africa, snapping up Turkish CRO Atlas Medical Services.

Through the deal, Parexel is getting a 35-employee outfit with offices in Istanbul, Ankara and Izmir and relationships across the region. Parexel isn't disclosing a price tag, saying only that its acquisition will fold into the company's existing clinical research services segment. Atlas brought in about $4 million in revenue last year, the company said, and Parexel doesn't expect the buyout to impact its financial guidance.

Despite its small size, Atlas boasts a client roster of more than 28 biopharma outfits including some of the world's largest drugmakers, Parexel said, and absorbing its operations will strengthen the company's presence in Turkey, the Middle East and North Africa, CEO Josef von Rickenbach said.

"These markets are of increasing importance to our clients who are looking for market access and a broad spectrum of patient populations for clinical trials," von Rickenbach said in a statement. "In addition, Atlas has been a trusted business partner to Parexel for many years, and their infrastructure and staff are already aligned with our processes and operations."

Meanwhile, Parexel is gearing up for its biggest year yet, projecting to make up to $2.2 billion in revenue in fiscal 2015. That would spell 10% annual growth and another double-digit boost for the Boston company, which leapt 12% last year. Parexel has attributed its steady growth to maintaining relationships with Big Pharma but also mounting momentum among small and mid-sized drugmakers.

The company is in the midst of a rebranding effort through which it hopes to better establish itself in the competition between the largest players in an increasingly top-heavy market. The goal is to better define Parexel's disparate offerings as a continuum of services, CEO von Rickenbach has said, and the CRO has retitled its banner eClinical business to bear the company's name.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库